Literature DB >> 23921256

Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO.

Doris E Payer1, Arian Behzadi1, Stephen J Kish2, Sylvain Houle3, Alan A Wilson4, Pablo M Rusjan5, Junchao Tong6, Peter Selby7, Tony P George8, Tina McCluskey9, Isabelle Boileau10.   

Abstract

The dopamine system is a primary treatment target for cocaine dependence (CD), but research on dopaminergic abnormalities (eg, D2 receptor system deficiencies) has so far failed to translate into effective treatment strategies. The D3 receptor system has recently attracted considerable clinical interest, and D3 antagonism is now under investigation as a novel avenue for addiction treatment. The objective here was to evaluate the status and behavioral relevance of the D3 receptor system in CD, using the positron emission tomography (PET) radiotracer [(11)C]-(+)-PHNO. Fifteen CD subjects (many actively using, but all abstinent 7-240 days on scan day) and fifteen matched healthy control (HC) subjects completed two PET scans: one with [(11)C]-(+)-PHNO to assess D3 receptor binding (BPND; calculated regionally using the simplified reference tissue model), and for comparison, a second scan with [(11)C]raclopride to assess D2/3 binding. CD subjects also completed a behavioral battery to characterize the addiction behavioral phenotype. CD subjects showed higher [(11)C]-(+)-PHNO BPND than HC in the substantia nigra, which correlated with behavioral impulsiveness and risky decision making. In contrast, [(11)C]raclopride BPND was lower across the striatum in CD, consistent with previous literature in 2 week abstinence. The data suggest that in contrast to a D2 deficiency, CD individuals may have heightened D3 receptor levels, which could contribute to addiction-relevant traits. D3 upregulation is emerging as a biomarker in preclinical models of addiction, and human PET studies of this receptor system can help guide novel pharmacological strategies for treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921256      PMCID: PMC3870773          DOI: 10.1038/npp.2013.192

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  47 in total

1.  Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART).

Authors:  C W Lejuez; Jennifer P Read; Christopher W Kahler; Jerry B Richards; Susan E Ramsey; Gregory L Stuart; David R Strong; Richard A Brown
Journal:  J Exp Psychol Appl       Date:  2002-06

2.  Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Authors:  Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

3.  The effects of the dopamine D₃ receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects.

Authors:  Pradeep J Nathan; Barry V O'Neill; Karin Mogg; Brendan P Bradley; John Beaver; Massimo Bani; Emilio Merlo-Pich; Paul C Fletcher; Bridget Swirski; Annelize Koch; Chris M Dodds; Edward T Bullmore
Journal:  Int J Neuropsychopharmacol       Date:  2011-07-12       Impact factor: 5.176

4.  A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale.

Authors:  R P Snaith; M Hamilton; S Morley; A Humayan; D Hargreaves; P Trigwell
Journal:  Br J Psychiatry       Date:  1995-07       Impact factor: 9.319

5.  Internal consistencies of the original and revised Beck Depression Inventory.

Authors:  A T Beck; R A Steer
Journal:  J Clin Psychol       Date:  1984-11

6.  Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain.

Authors:  Nathalie Ginovart; Matthaeus Willeit; Pablo Rusjan; Ariel Graff; Peter M Bloomfield; Sylvain Houle; Shitij Kapur; Alan A Wilson
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-11       Impact factor: 6.200

7.  BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization.

Authors:  O Guillin; J Diaz; P Carroll; N Griffon; J C Schwartz; P Sokoloff
Journal:  Nature       Date:  2001-05-03       Impact factor: 49.962

8.  D3 dopamine autoreceptors do not activate G-protein-gated inwardly rectifying potassium channel currents in substantia nigra dopamine neurons.

Authors:  Viviana Davila; Zhen Yan; Liviu C Craciun; Diomedes Logothetis; David Sulzer
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

9.  Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Authors:  Ariel Graff-Guerrero; Matthaeus Willeit; Nathalie Ginovart; David Mamo; Romina Mizrahi; Pablo Rusjan; Irina Vitcu; Philip Seeman; Alan A Wilson; Shitij Kapur
Journal:  Hum Brain Mapp       Date:  2008-04       Impact factor: 5.038

10.  Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.

Authors:  Manolo Mugnaini; Laura Iavarone; Palmina Cavallini; Cristiana Griffante; Beatrice Oliosi; Chiara Savoia; John Beaver; Eugenii A Rabiner; Fabrizio Micheli; Christian Heidbreder; Anne Andorn; Emilio Merlo Pich; Massimo Bani
Journal:  Neuropsychopharmacology       Date:  2012-09-12       Impact factor: 7.853

View more
  56 in total

1.  Effects of oral and intravenous administration of buspirone on food-cocaine choice in socially housed male cynomolgus monkeys.

Authors:  Paul W Czoty; Michael A Nader
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

2.  Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.

Authors:  David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson
Journal:  Neuroimage       Date:  2016-02-11       Impact factor: 6.556

3.  Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.

Authors:  Isabelle Boileau; Doris Payer; Pablo M Rusjan; Sylvain Houle; Junchao Tong; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

4.  Effects of chronic binge-like ethanol consumption on cocaine self-administration in rhesus monkeys.

Authors:  Paul W Czoty
Journal:  Drug Alcohol Depend       Date:  2015-05-21       Impact factor: 4.492

5.  Dopamine D3 Receptor Antagonist (GSK598809) Potentiates the Hypertensive Effects of Cocaine in Conscious, Freely-Moving Dogs.

Authors:  Nathan M Appel; Shou-Hua Li; Tyson H Holmes; Jane B Acri
Journal:  J Pharmacol Exp Ther       Date:  2015-07-15       Impact factor: 4.030

6.  Addiction-related genes in gambling disorders: new insights from parallel human and pre-clinical models.

Authors:  D S S Lobo; L Aleksandrova; J Knight; D M Casey; N el-Guebaly; J N Nobrega; J L Kennedy
Journal:  Mol Psychiatry       Date:  2014-09-30       Impact factor: 15.992

7.  Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Authors:  Claudia Rangel-Barajas; Maninder Malik; Michelle Taylor; Kim A Neve; Robert H Mach; Robert R Luedtke
Journal:  J Neurochem       Date:  2014-08-19       Impact factor: 5.372

8.  Further characterization of quinpirole-elicited yawning as a model of dopamine D3 receptor activation in male and female monkeys.

Authors:  Susan E Martelle; Susan H Nader; Paul W Czoty; William S John; Angela N Duke; Pradeep K Garg; Sudha Garg; Amy H Newman; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2014-05-29       Impact factor: 4.030

9.  D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction.

Authors:  Esmaeil Mansouri; José N Nobrega; Matthew N Hill; Rachel F Tyndale; Francis S Lee; Christian S Hendershot; Laura M Best; Patricia Di Ciano; Georgia Balsevich; Mathew E Sloan; Stephen J Kish; Junchao Tong; Bernard Le Foll; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2019-11-27       Impact factor: 7.853

10.  In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO.

Authors:  I Boileau; D Payer; B Chugani; D S S Lobo; S Houle; A A Wilson; J Warsh; S J Kish; M Zack
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.